{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"DLT is drug-related events with onset within first 28 days following infusion:\n\n* Grade (GR) 4 hematologic toxicity lasting more than 30 days (except lymphopenia) if not attributable to underlying disease\n* All drug-related GR 3 lasting for \\> 7 days or 4 non-hematologic toxicities regardless of duration (except: aphasia/dysphasia or confusion/cognitive disturbance which resolves to at least GR 1/baseline within 2 weeks or baseline within 4 weeks, fever GR 3/ 4, immediate hypersensitivity reactions within 2 hours of drug infusion that are reversible ≤ GR 2 within 24 hours, renal toxicity which requires dialysis for ≤ 7 days, intubation for airway protection if ≤ 7 days, tumor lysis syndrome, GR 3 liver function test elevation, provided there is resolution to ≤ GR 2 within 14 days, GR 4 transient serum hepatic enzyme abnormalities provided there is resolution to ≤ GR 3 within \\< 72 hours, hypogammaglobulinemia GR 3/ 4 and GR 3 nausea and/or anorexia).","groups":[{"description":"Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \\> 100 kg, a maximum flat dose of 2 x 10\\^8 anti-CD19 CAR T cells/kg of body weight was administered.","id":"OG000","title":"Phase 1: 2 x 10^6 Anti-CD19 CAR T Cells/kg"}],"paramType":"NUMBER","populationDescription":"DLT-Evaluable Analysis Set included first 3 participants in Phase 1 treated with target brexucabtagene autoleucel dose and followed for at least 28 days. Only participants from Phase 1: 2 X 10\\^6 Anti-CD19 CAR T Cells/kg were pre-specified to be assessed for this Outcome Measure.","reportingStatus":"POSTED","timeFrame":"First infusion date of brexucabtagene autoleucel up to 28 days. Participants were evaluated in specified period but GR4 hematologic toxicity (specified in description) having onset in this period were further observed for 30 days for confirmation","title":"Phase 1: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}